Anemia, which is a condition where red blood cells are deficient for oxygen, is a major health problem. It is common among pregnant women, and is more so among infants. It is thought to be associated with higher blood pressure, strokes, heart attacks and death.\n
Anemia is an important cause of morbidity and mortality in the pediatric sickle cell population. With increased utilization of transfusions in the NICU, an increasing number of infants with sickle cell disease (S/T) are at risk for the development of anemia. The use of RBC transfusions on patients with S/T is associated with an increasing need to obtain posttransfusion hemoglobin levels as well as increased odds ratios for severe anemia and death in the NICU.
The signs of anemia from a lack of iron can include pale skin, dark rings around the eyes, difficulty breathing and vomiting. For sickle cell anaemia, the signs of pain and swelling may be present. Pains often feel like sharp spasm-like pains that radiate from the joints. Other signs of sickle cell anaemia, which can mimic that of malaria, include low body temperature and rapid pulse rate (often referred to as a 'high pulse'). People must be educated on the risks of fever, high and low (very low) body temperatures. The swelling of sickle cell crises can be so painful that people may seek emergency help before the symptoms resolve.
Anemia, which affects 3.1 million people in the United States, is caused by an increased red blood cell turnover or decreased production due to reduced hemoglobin levels; or both, thus inducing microcytic anemia.
About one in ten of the US American population would be an anemic person, with sickle cell disease being more commonly seen. The total number of children with sickle cell anemia appears to be around one thousand a year. It is estimated that this condition causes an important number of deaths.
The causes for sickle cell disease are varied, ranging from the hereditary disorder and heredity to environmental and other causes. Most commonly, this disease can be attributed to a sickle cell allele in combination with other hemoglobin alleles that predispose to sickle cell disease. Anemia is an important cause of morbidity in the United States.
Mitoq was safe and well tolerated in adult outpatients with sickle cell disease or thalassemia. The data support further efforts to develop Mitoq for use in pediatric patients with sickle cell disease.
While the results of this study (the MitoQ and placebo groups had similar hemoglobin and serum ferritin levels) reveal no improvement in anemia or the number of sickle cell crises, the incidence of anemia did not increase in the MitoQ group.
Physicians should consider clinical trials of the drug candidates if they anticipate a potential patient who could benefit from the drug, have a reasonable likelihood that they could take the medication, and are willing to support drug therapy or participation in research.
A new finding for treating anemia of chronic disease is erythropoietin, which appears to improve anemia of chronic disease by increasing production of red blood cells and by enhancing the function of existing cells. If such treatments become available, they may become standard treatments for anemia of chronic disease.
There is a lot of research relating to mitoq as treatment for anemia but what is the current status of research in mitoq, ixridutum, and ferrioxalate?
(1) In a recently published clinical trial with a very low number of patients (n = 15), there was no signficant difference in the overall quality of life of sickle cell disease patients with or without HbF and when treated with mitoq. (2) There have been two other reports concerning mitoq treatment with positive results: the reduction in the need for blood transfusions in young black women and no effect on sickle-related complications. A Cochrane review (www.cochrane.